News topic
News News & Updates
Breaking and short-form coverage of events in the peptide space.
9 articles in this topic
When Will Retatrutide Be FDA Approved? The 2026 Timeline Explained
With Phase 3 results showing 24% mean weight loss, retatrutide is poised to become the most effective weight-loss drug ever approved. But when will patients actually get it, and what does the timeline look like from here?
Foundayo (Orforglipron) FDA Approved: The First GLP-1 Pill You Can Take Any Time of Day
On April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's once-daily oral GLP-1 receptor agonist for weight loss. Unlike existing oral semaglutide, Foundayo can be taken any time of day without food or water restrictions, starting at $149/month.
FDA Removes 12 Peptides from Category 2: BPC-157, TB-500, Semax, and More No Longer Flagged as Safety Risks
On April 15, 2026, the FDA announced the removal of 12 peptide bulk drug substances from Category 2 — the list reserved for compounds with significant safety concerns. BPC-157, TB-500, Semax, MOTS-c, GHK-Cu (injectable), and seven others are affected. Here is what it means.
Medicare GLP-1 Bridge: $50/Month Weight Loss Drugs Starting July 2026
CMS announced the Medicare GLP-1 Bridge — a demonstration program offering eligible Medicare beneficiaries access to FDA-approved weight loss drugs for $50 per month starting July 1, 2026. Here is everything you need to know.
FDA Proposes Permanent Ban on Compounded Semaglutide and Tirzepatide
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively ending large-scale compounding of GLP-1 drugs. Comments are due June 29.
Oral GLP-1 Drugs Penetrate Deep Into the Brain to Suppress Cravings, NIH Study Finds
A landmark NIH-funded study published in Nature reveals that oral small-molecule GLP-1 drugs like orforglipron reach deep brain reward circuits — specifically the central amygdala — to suppress cravings for pleasurable food. The finding opens a new pathway for treating addiction.
Inside the FDA Peptide Advisory Committee: What to Expect at the July 23–24 PCAC Meeting
The FDA’s Pharmacy Compounding Advisory Committee meets July 23–24 to vote on whether BPC-157, TB-500, Semax, Epitalon, MOTS-c, KPV, and DSIP should return to the compounding list. With 6 of 10 seats vacant and allegations of committee stacking, the outcome could reshape peptide access.
Tirzepatide Linked to Lower Mortality Than Semaglutide in 127,000-Patient Real-World Study
A real-world study of 253,942 matched patients presented at Digestive Disease Week 2026 found that tirzepatide was associated with significantly lower all-cause mortality and fewer adverse gastrointestinal events compared to semaglutide.
AI Scans 400,000 Reddit Posts to Flag Overlooked GLP-1 Side Effects
Penn Engineering researchers used AI to analyze over 400,000 Reddit posts from nearly 70,000 users, identifying potential GLP-1 side effects — including menstrual irregularities and temperature-related symptoms — that may not be captured in clinical trials.